Marksans Pharma Ltd. (MARKSANS): Marksans Pharma Share Price Near 52-Week High After 3.8% Rise
- September 23, 2026
- Posted by: Chaitanya Auti
- Category: News
Marksans Pharma Share Price is in focus after the stock moved to Rs 344.2, up 3.8% from the previous close, and remained close to its 52-week high zone. Marksans Pharma Ltd. (MARKSANS) has a market capitalisation of Rs 15,267.09 crore, putting the latest Marksans Pharma Share Price Today move into a clearly defined market context. The latest Marksans Pharma figures show a firm intraday range, with the stock trading between Rs 334.05 and Rs 344.5 during the morning session. This Marksans Pharma Stock News update confirms the price event, but it does not establish a company-specific catalyst. Univest is tracking the move because the share price is now near a yearly high while valuation and sector comparisons remain relevant.
Marksans Pharma Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 344.2 |
| Previous Close | Rs 331.6 |
| Today's Move | +Rs 12.6 (+3.8%) |
| Open | Rs 334.05 |
| High | Rs 344.5 |
| Low | Rs 334.05 |
| Market Capitalisation | Rs 15,267.09 crore |
Marksans Pharma Ltd. (MARKSANS) traded at Rs 344.2 versus the previous close of Rs 331.6, a rise of 3.8%. The stock opened at Rs 334.05, reached a high of Rs 344.5 and touched a low of Rs 334.05.
Marksans Pharma Share Price Today shows the stock at Rs 344.2 versus the previous close of Rs 331.6, a day gain of Rs 12.6 or 3.8%. The Marksans Pharma Share Price opened at Rs 334.05 and touched a high of Rs 344.5, with the low also at Rs 334.05. That places the Marksans Pharma Share Price very close to its 52-week high zone during the current trade, which is why the stock is appearing in Marksans Pharma Stock News and Marksans Pharma Share News screens. For readers following Marksans Pharma Share Price Live, the event is a near-high price move rather than a claim of a fresh record. Univest is highlighting the price action because the stock is trading at the upper end of its daily range.
Marksans Pharma Ltd. (MARKSANS) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,267.09 crore |
| P/E Ratio | 29.08x |
| P/B Ratio | 4.73x |
| ROE | 15.31% |
| ROCE | 21.1% |
| EPS | Rs 11.4 |
| Book Value Per Share | Rs 70.16 |
| Dividend Yield | 0.27% |
Marksans Pharma Ltd. (MARKSANS) fundamental metrics show P/E 29.08x, P/B 4.73x, ROE 15.31%, ROCE 21.1%. These figures provide context only and are not a buy or sell signal.
Marksans Pharma Ltd. has a market capitalisation of Rs 15267.09 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 29.08x, P/B at 4.73x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 15.31% and ROCE of 21.1%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 11.4, book value per share of Rs 70.16, dividend yield of 0.27%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 27.91x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 29.08x |
| Benchmark Median P/E | 27.91x |
| Benchmark Average P/E | 41.68x |
| Benchmark P/E Range | 0x to 707.31x |
| Company P/B Ratio | 4.73x |
| Benchmark Median P/B | 2.83x |
| Company ROE | 15.31% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 21.1% |
| Benchmark Median ROCE | 13.46% |
| Company Market Capitalisation | Rs 15,267.09 crore |
| Benchmark Median Market Cap | Rs 782.41 crore |
Marksans Pharma Ltd. (MARKSANS) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Marksans Pharma Ltd. (MARKSANS) has a P/E ratio of 29.08x, which is above the benchmark median of 27.91x, a difference of +4.19%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Marksans Pharma Ltd. (MARKSANS) has a ROE of 15.31%, which is above the benchmark median of 11.7%, a difference of +30.85%. Marksans Pharma Ltd. (MARKSANS) has a ROCE of 21.1%, which is above the benchmark median of 13.46%, a difference of +56.76%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Concord Biotech Ltd. | CONCORDBIO | 15,213.29 | 52.96 | 7.03 | 13.54 | 18.04 |
| Natco Pharma Ltd. | NATCOPHARM | 15,046.12 | 12.96 | 1.59 | 16.3 | 17.16 |
| Astrazeneca Pharma India Ltd. | ASTRAZEN | 15,718.75 | 92.67 | 17.38 | 23.02 | 31.24 |
| Glenmark Life Sciences Ltd. | ALIVUS | 16,510.3 | 27.38 | 4.74 | 18.41 | 24.61 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,975.19 | 24.21 | 2.87 | 12.35 | 11.74 |
Marksans Pharma Ltd. (MARKSANS) has a P/E ratio of 29.08x compared with the displayed peer median of 27.38x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 15.31% compares with a peer median of 16.3% across the companies shown in the table. ROCE stood at 21.1% versus the displayed peer median of 18.04%, providing a capital-efficiency comparison. Marksans Pharma Ltd. (MARKSANS) has a market capitalisation of Rs 15,267.09 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Marksans Pharma
- Marksans Pharma Share Price is at Rs 344.2, up 3.8% from the previous close.
- The stock is trading near its 52-week high zone and one-year high zone.
- Market capitalisation stands at Rs 15,267.09 crore.
- P/E is 29.08, P/B is 4.73, ROE is 15.31% and ROCE is 21.1%.
- Revenue moved from Rs 6,199.89 crore in Jun 25 to Rs 8,407.96 crore in Jun 26.
About Marksans Pharma
Marksans Pharma Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is referenced in Marksans Pharma Stock News and Marksans Pharma Company News because the latest price action places Marksans Pharma Share Price near a yearly high. Marksans Pharma Share Price Today also remains relevant because the business metrics available include market cap, earnings per share, book value and dividend yield. Univest presents the company profile through the same factual lens used in Marksans Pharma Share Price Update coverage.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
Why is Marksans Pharma Share Price in focus today?
Ans. Marksans Pharma Share Price is in focus because it rose 3.8% to Rs 344.2 and stayed near its 52-week high zone. The move is factual, while the data does not identify a company-specific catalyst.
What is Marksans Pharma Share Price Today?
Ans. Marksans Pharma Share Price Today is Rs 344.2. It is above the previous close of Rs 331.6 and sits close to the yearly high zone, which is why the stock is appearing in market screens.
What is the market capitalisation of Marksans Pharma?
Ans. Marksans Pharma has a market capitalisation of Rs 15,267.09 crore. That places the company in a significant market-cap bracket within its industry and gives context to the current Marksans Pharma Share Price move.
How does Marksans Pharma compare on valuation?
Ans. Marksans Pharma trades at a P/E of 29.08 and a P/B of 4.73. Its P/E is above the industry median of 27.91, while P/B is above the industry median of 2.83.
What profitability metrics are available for Marksans Pharma Share Price analysis?
Ans. The available profitability metrics include ROE of 15.31%, ROCE of 21.1% and EPS of 11.4. These figures help explain the financial context behind Marksans Pharma Share Price and its current near-high placement.
What does the sector comparison show for Marksans Pharma?
Ans. Marksans Pharma operates in Healthcare and Pharmaceuticals & Drugs. Its ROE and ROCE are above the industry median, while its P/E is slightly above the median and below the industry average.
How does Marksans Pharma compare with peers?
Ans. Compared with peers such as Concord Biotech, Natco Pharma and Alembic Pharmaceuticals, Marksans Pharma Share Price sits in a middle valuation range. Its profitability ratios compare favourably with several listed peers.
What should readers track next for Marksans Pharma Share Price?
Ans. Readers can track Marksans Pharma Share Price on Univest for live price updates, valuation ratios, sector context, peer comparison and company news. The next visible checkpoint is whether the stock keeps trading near its 52-week high zone.
Track Marksans Pharma Share Price on Univest
Use Marksans Pharma Ltd. (MARKSANS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
You can track Marksans Pharma Share Price on Univest for live price updates, key valuation ratios, financial ratios, company news, and the latest share price move. Marksans Pharma Share Price Live coverage on Univest also helps readers follow the 52-week high, sector comparison and peer context in one place. Univest keeps the Marksans Pharma Share Price Today view focused on verified market data.